English

SpectraCure AB Year-end report 1 January – 31 December 2018

Report this content

Fourth quarter (1 October – 31 December 2018)

  • Net sales for the quarter amounted to TSEK 0 (0).
  • Operating profit (EBIT) was TSEK -3 249 (-2 599).
  • Operating cash flow was TSEK -3 806 (-2 632).
  • Profit after tax amounted to TSEK -3 242 (-2 599).
  • Corresponding to SEK -0,04 (-0,04) per share.

Full-year (1 January – 31 December 2018)

  • Net sales for the period amounted to MSEK 0 (0).
  • Operating profit (EBIT) was TSEK -11 821 (-8 535).
  • Operating cash flow was TSEK -10 864 (-9 095).
  • Profit after tax amounted to TSEK -11 814 (-8 535).
  • Corresponding to SEK -0,16 (-0,14) per share.

For further information, please contact:
SpectraCure AB publ, CEO, Masoud Khayyami, phone: +46 (0) 70 815 21 90

Certified Adviser is G&W Fondkommission, e-mail: ca@gwkapital.se, phone: +46(0) 8 503 000 50 

This information is information that SpectraCure AB is required to disclose under the EU Market Abuse Regulation. The information was provided, through the contact of the above contact person, for publication on February 15th, 2019.

SpectraCure in short

SpectraCure was founded in 2003 as a spin off from Lund University departments for medical laser applications and physics. The company focuses on cancer treatments using medical systems with laser light sources and reactive drugs, which is referred to as "Interstitial Photodynamic Therapy", PDT, a treatment methodology suitable for internal solid tumours of various kind, e.g. prostate and abdominal salivary glands, but also other indications such as cancer tumours in the head and neck region

Tags:

clinical study prostate cancer spectracure PDT

Documents & Links